POPPY Waves 4 & 5
Research type
Research Study
Full title
A prospective, observational study to examine the effects of ageing on the clinical outcomes of people living with HIV in England and Ireland - Waves 4 and 5 POPPY 4 & 5 – ‘Pharmacokinetic and Clinical Observations in People over Fifty Waves 4 and 5
IRAS ID
255779
Contact name
Alan Winston
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Our study is a continuation of the POPPY Study (Pharmacokinetic and Clinical Observations in People Over Fifty) and the aim is for 1,377 study participants who completed visits 1-3 to join this new study waves 4 and 5. It is an observational study(participants will receive standard care and treatment is not determined by the study protocol) taking place at 8 hospitals in the UK and Ireland.
This study is being funded by Gilead Sciences and ViiV Healthcare, and it is anticipated it will take around 2 years to complete the visits on 1,377 participants.
Analyses from the first 3 visits of the POPPY study have included detailed description of cognitive function, bone health, mental health and antiretroviral drug exposure in PLWH with several novel and clinically important findings.
This study will continue to investigate the impact of older age on the experience of living with HIV in England and Ireland. In particular, we are interested in documenting the medical conditions that cause problems to older PLWH, and the effect of these medical conditions (and any treatment received) on their lives and their HIV care.The research will involve 2 study visits at the clinic which are expected to take up to 4 hours and all study participants will be followed over two years.
At each visit, participants will undergo a clinical examination (including cognitive testing at wave 5 visit) and will be asked to complete questionnaires about their health, lifestyle and quality of life over the past year. Respiratory function will be assessed at wave 4 visit. A scan of bone density (DXA scan) will be performed at wave 5 visit. This would detect any signs of osteoporosis or bone thinning. Blood and urine samples will be stored for future analysis. Drug exposure will be determined for those on HIV treatment.REC name
London - Chelsea Research Ethics Committee
REC reference
19/LO/0755
Date of REC Opinion
27 Jun 2019
REC opinion
Further Information Favourable Opinion